Bayer


Dividend cut to the minimal amount as last line of defence

19/02/24 -"Bayer has announced a dividend cut to the legally-required minimum of 4% of AG capital, which translates to a dividend proposal of 11 euro cents (2022: €2.40 – consensus: €1.92) at the AGM on 26 ..."

Pages
72
Language
English
Published on
19/02/24
You may also be interested by these reports :
13/08/26
PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus ...

13/08/26
The Q2 results surpassed expectations, backed by the unrelenting growth of Dupixent and the impressive uptake of some newly launched medicines. ...

12/08/26
With the Astra-BMS merger idea likely being shelved after apprehensions raised by various analysts/investors, we re-float the idea of an Astra-GSK ...

04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO